Page 145 - Eceptor News Today

Researchers reported an epitope with high potency and breadth and demonstrated that a therapeutic antibody directed at this site neutralizes all SARS-CoV-2 variants.

Researchers developed covalent nanobodies to neutralize severe acute respiratory syndrome coronavirus-2 and its variants.

Researchers constructed a novel fusion inhibitor−based recombinant protein, referred to as 5−Helix, to block SARS-CoV-2 spike-mediated cell-cell fusion.

Mont-Saint-Guibert, Belgium - Celyad Oncology SA , a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer,... | March 17, 2022

Researchers assessed the safety profile and immunogenicity of a heterologous NVSI-06-08 boost against SARS-CoV-2 variants in individuals doubly vaccinated with the inactivated vaccine BBIBP-CorV.

Researchers reported the association of a single nucleotide polymorphism rs9984273 in the interferon-alpha/beta receptor gene with outcomes of acute respiratory distress syndrome and COVID-19.

Researchers explored neuroinflammation and COVID-19-induced ischemic stroke recovery.

Researchers use molecular docking to screen phytocompounds and evaluate their binding affinity with SARS-CoV-2.

Researchers evaluate the feasibility of tonsil epithelial cell-derived organoids as an ex vivo model for studying SARS-CoV-2 infection.

A new study identified additional targets on SARS-CoV-2 proteins to prevent the emergence of new SARS-CoV-2 variants of concern.